Transcriptomic FHIT(low)/pHER2(high) signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer

por Brisebarre, Audrey, Ancel, Julien, Ponchel, Théophile, Loeffler, Emma, Germain, Adeline, Dalstein, Véronique, Dormoy, Valérian, Durlach, Anne, Delepine, Gonzague, Deslée, Gaëtan, Polette, Myriam, Nawrocki-Raby, Béatrice
Publicado 2022